What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker's Bureau - Vectorious Medical; Respicardia; Boehringer Ingelheim; Cordio; Impulse Dynamics; White Swell
- Salary/Salary Support/Employee - V-WaveMedical
- Equity/Stock(s)/Options - Cardionomic